581 related articles for article (PubMed ID: 31894255)
21. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).
Katoh M
Int J Oncol; 2017 Nov; 51(5):1357-1369. PubMed ID: 29048660
[TBL] [Abstract][Full Text] [Related]
22. Notch signaling dynamics in the adult healthy prostate and in prostatic tumor development.
Pedrosa AR; Graça JL; Carvalho S; Peleteiro MC; Duarte A; Trindade A
Prostate; 2016 Jan; 76(1):80-96. PubMed ID: 26419726
[TBL] [Abstract][Full Text] [Related]
23. Notch signaling as a therapeutic target for acute lymphoblastic leukemia.
Bellavia D; Palermo R; Felli MP; Screpanti I; Checquolo S
Expert Opin Ther Targets; 2018 Apr; 22(4):331-342. PubMed ID: 29527929
[TBL] [Abstract][Full Text] [Related]
24. Notch signaling: emerging molecular targets for cancer therapy.
Yin L; Velazquez OC; Liu ZJ
Biochem Pharmacol; 2010 Sep; 80(5):690-701. PubMed ID: 20361945
[TBL] [Abstract][Full Text] [Related]
25. Targeting Notch signaling for cancer therapeutic intervention.
Shao H; Huang Q; Liu ZJ
Adv Pharmacol; 2012; 65():191-234. PubMed ID: 22959027
[TBL] [Abstract][Full Text] [Related]
26. Expression pattern of notch1, 2 and 3 and Jagged1 and 2 in lymphoid and stromal thymus components: distinct ligand-receptor interactions in intrathymic T cell development.
Felli MP; Maroder M; Mitsiadis TA; Campese AF; Bellavia D; Vacca A; Mann RS; Frati L; Lendahl U; Gulino A; Screpanti I
Int Immunol; 1999 Jul; 11(7):1017-25. PubMed ID: 10383933
[TBL] [Abstract][Full Text] [Related]
27. Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers.
Katoh M
Clin Sci (Lond); 2019 Apr; 133(8):953-970. PubMed ID: 31036756
[TBL] [Abstract][Full Text] [Related]
28. WNT signaling pathway and stem cell signaling network.
Katoh M; Katoh M
Clin Cancer Res; 2007 Jul; 13(14):4042-5. PubMed ID: 17634527
[TBL] [Abstract][Full Text] [Related]
29. Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.
Shi Q; Xue C; Zeng Y; Yuan X; Chu Q; Jiang S; Wang J; Zhang Y; Zhu D; Li L
Signal Transduct Target Ther; 2024 May; 9(1):128. PubMed ID: 38797752
[TBL] [Abstract][Full Text] [Related]
30. Targeting oncogenic Notch signaling with SERCA inhibitors.
Pagliaro L; Marchesini M; Roti G
J Hematol Oncol; 2021 Jan; 14(1):8. PubMed ID: 33407740
[TBL] [Abstract][Full Text] [Related]
31. Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview.
Matsuo K; Taniguchi K; Hamamoto H; Inomata Y; Komura K; Tanaka T; Lee SW; Uchiyama K
Cancer Sci; 2021 Aug; 112(8):2984-2992. PubMed ID: 34107132
[TBL] [Abstract][Full Text] [Related]
32. Notch Signaling: A Potential Therapeutic Target for Hematologic Malignancies.
Gao L; Yuan K; Ding W; Lin M
Crit Rev Eukaryot Gene Expr; 2016; 26(3):239-46. PubMed ID: 27650987
[TBL] [Abstract][Full Text] [Related]
33. [Therapeutic targeting of Notch signaling in cancer].
Brahmi M; Bally O; Eberst L; Cassier P
Bull Cancer; 2017 Oct; 104(10):883-891. PubMed ID: 29031504
[TBL] [Abstract][Full Text] [Related]
34. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers.
Haruki N; Kawaguchi KS; Eichenberger S; Massion PP; Olson S; Gonzalez A; Carbone DP; Dang TP
Cancer Res; 2005 May; 65(9):3555-61. PubMed ID: 15867348
[TBL] [Abstract][Full Text] [Related]
35. Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings.
Goruganthu MUL; Shanker A; Dikov MM; Carbone DP
Front Immunol; 2020; 11():1958. PubMed ID: 32922403
[TBL] [Abstract][Full Text] [Related]
36. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
Su PL; Chakravarthy K; Furuya N; Brownstein J; Yu J; Long M; Carbone D; Li Z; He K
Mol Cancer; 2024 May; 23(1):97. PubMed ID: 38730427
[TBL] [Abstract][Full Text] [Related]
37. Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells.
Katoh M
Curr Pharm Biotechnol; 2011 Feb; 12(2):160-70. PubMed ID: 21044011
[TBL] [Abstract][Full Text] [Related]
38. Salvianolic Acid B Enhances Hepatic Differentiation of Human Embryonic Stem Cells Through Upregulation of WNT Pathway and Inhibition of Notch Pathway.
Chen J; Tschudy-Seney B; Ma X; Zern MA; Liu P; Duan Y
Stem Cells Dev; 2018 Feb; 27(4):252-261. PubMed ID: 29256825
[TBL] [Abstract][Full Text] [Related]
39. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
[TBL] [Abstract][Full Text] [Related]
40. The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice.
Deng SM; Yan XC; Liang L; Wang L; Liu Y; Duan JL; Yang ZY; Chang TF; Ruan B; Zheng QJ; Han H
Biochem Biophys Res Commun; 2017 Jan; 483(1):488-494. PubMed ID: 28007595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
